{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Carcinoma", "query": { "condition": "Malignant Carcinoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 772, "total_pages": 78, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Carcinoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-16T18:13:00.337Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04726332", "title": "Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasm Malignant", "Epithelial Ovarian Cancer", "Triple Negative Breast Cancer", "Hormone Receptor Positive Breast Carcinoma", "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "XL102", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2021-02-10", "completion_date": "2024-05-02", "has_results": false, "last_update_posted_date": "2024-05-14", "last_synced_at": "2026-09-16T18:13:00.337Z", "location_count": 5, "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Dallas, Texas + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04726332" }, { "nct_id": "NCT03436563", "title": "M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colon Adenocarcinoma", "High-Frequency Microsatellite Instability", "Metastatic Malignant Solid Neoplasm", "Rectal Adenocarcinoma", "Refractory Colorectal Carcinoma", "Stage IV Colon Cancer AJCC v8", "Stage IV Rectal Cancer AJCC v8", "Stage IVA Colon Cancer AJCC v8", "Stage IVA Rectal Cancer AJCC v8", "Stage IVB Colon Cancer AJCC v8", "Stage IVB Rectal Cancer AJCC v8" ], "interventions": [ { "name": "Anti-PD-L1/TGFbetaRII Fusion Protein M7824", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2018-03-07", "completion_date": "2023-08-08", "has_results": true, "last_update_posted_date": "2024-11-27", "last_synced_at": "2026-09-16T18:13:00.337Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03436563" }, { "nct_id": "NCT03284385", "title": "Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Locally Advanced Clear Cell Renal Cell Carcinoma", "Locally Advanced Malignant Solid Neoplasm", "Metastatic Malignant Solid Neoplasm", "Metastatic Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Adavosertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2019-01-29", "completion_date": "2027-04-22", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-09-16T18:13:00.337Z", "location_count": 29, "location_summary": "Orange, California • Sacramento, California • San Francisco, California + 18 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03284385" }, { "nct_id": "NCT06171750", "title": "Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Cutaneous Tumor", "Subcutaneous Tumor", "Malignant Solid Tumor", "Solid Tumor", "Metastatic Solid Tumor", "Metastasis to Soft Tissue", "Non Small Cell Lung Cancer", "Cutaneous Squamous Cell Carcinoma" ], "interventions": [ { "name": "tolododekin alfa", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ankyra Therapeutics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 97, "start_date": "2024-01-19", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-03-06", "last_synced_at": "2026-09-16T18:13:00.337Z", "location_count": 4, "location_summary": "Bethesda, Maryland • Boston, Massachusetts • Portland, Oregon + 1 more", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Portland", "state": "Oregon" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06171750" }, { "nct_id": "NCT00492089", "title": "Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Anaplastic Astrocytoma", "Adult Anaplastic Ependymoma", "Adult Anaplastic Meningioma", "Adult Anaplastic Oligodendroglioma", "Adult Brain Stem Glioma", "Adult Central Nervous System Germ Cell Tumor", "Adult Choroid Plexus Tumor", "Adult Diffuse Astrocytoma", "Adult Ependymoma", "Adult Grade II Meningioma", "Adult Grade III Meningioma", "Adult Malignant Hemangiopericytoma", "Adult Mixed Glioma", "Adult Oligodendroglioma", "Adult Papillary Meningioma", "Adult Pineocytoma", "Malignant Neoplasm", "Meningeal Melanocytoma", "Radiation Toxicity", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Adult Brain Tumor", "Recurrent Basal Cell Carcinoma of the Lip", "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Lymphoepithelioma of the Nasopharynx", "Recurrent Lymphoepithelioma of the Oropharynx", "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Stage I Adenoid Cystic Carcinoma of the Oral Cavity", "Stage I Basal Cell Carcinoma of the Lip", "Stage I Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage I Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage I Lymphoepithelioma of the Nasopharynx", "Stage I Lymphoepithelioma of the Oropharynx", "Stage I Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage I Mucoepidermoid Carcinoma of the Oral Cavity", "Stage I Salivary Gland Cancer", "Stage I Squamous Cell Carcinoma of the Hypopharynx", "Stage I Squamous Cell Carcinoma of the Larynx", "Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage I Squamous Cell Carcinoma of the Nasopharynx", "Stage I Squamous Cell Carcinoma of the Oropharynx", "Stage I Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage I Verrucous Carcinoma of the Larynx", "Stage I Verrucous Carcinoma of the Oral Cavity", "Stage III Adenoid Cystic Carcinoma of the Oral Cavity", "Stage III Basal Cell Carcinoma of the Lip", "Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage III Lymphoepithelioma of the Nasopharynx", "Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage III Mucoepidermoid Carcinoma of the Oral Cavity", "Stage III Salivary Gland Cancer", "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Nasopharynx", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage III Verrucous Carcinoma of the Larynx", "Stage III Verrucous Carcinoma of the Oral Cavity", "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IV Basal Cell Carcinoma of the Lip", "Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Lymphoepithelioma of the Nasopharynx", "Stage IV Lymphoepithelioma of the Oropharynx", "Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IV Salivary Gland Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Verrucous Carcinoma of the Larynx", "Stage IV Verrucous Carcinoma of the Oral Cavity" ], "interventions": [ { "name": "bevacizumab", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "magnetic resonance imaging", "type": "PROCEDURE" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2007-06", "completion_date": "2010-08", "has_results": true, "last_update_posted_date": "2014-05-09", "last_synced_at": "2026-09-16T18:13:00.337Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00492089" }, { "nct_id": "NCT00405587", "title": "Safety Study of PLX4032 in Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Melanoma", "Colorectal Carcinoma" ], "interventions": [ { "name": "PLX4032", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Plexxikon", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 109, "start_date": "2006-11", "completion_date": "2016-02", "has_results": true, "last_update_posted_date": "2017-08-22", "last_synced_at": "2026-09-16T18:13:00.337Z", "location_count": 5, "location_summary": "Los Angeles, California • New York, New York • Philadelphia, Pennsylvania + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00405587" }, { "nct_id": "NCT00651716", "title": "T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Chronic Myeloproliferative Disorders", "Gestational Trophoblastic Tumor", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Neuroblastoma", "Ovarian Cancer", "Testicular Germ Cell Tumor" ], "interventions": [ { "name": "flow cytometry", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "Data Collection", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 150, "start_date": "2006-12", "completion_date": "2019-10", "has_results": false, "last_update_posted_date": "2019-11-15", "last_synced_at": "2026-09-16T18:13:00.337Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00651716" }, { "nct_id": "NCT05737706", "title": "Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Advanced Solid Tumor", "Non-small Cell Lung Cancer", "Colo-rectal Cancer", "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "MRTX1133", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirati Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2023-03-06", "completion_date": "2025-03-10", "has_results": false, "last_update_posted_date": "2025-04-06", "last_synced_at": "2026-09-16T18:13:00.337Z", "location_count": 14, "location_summary": "Phoenix, Arizona • New Haven, Connecticut • Lady Lake, Florida + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Lady Lake", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05737706" }, { "nct_id": "NCT06974734", "title": "A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Non Small Cell Lung", "Carcinoma, Pancreatic Ductal", "Malignant Melanoma", "Squamous Cell Carcinoma of the Head and Neck (SCCHN)" ], "interventions": [ { "name": "PF-08046037", "type": "DRUG" }, { "name": "sasanlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2025-05-06", "completion_date": "2026-03-31", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-09-16T18:13:00.337Z", "location_count": 14, "location_summary": "Denver, Colorado • New Haven, Connecticut • Trumbull, Connecticut + 3 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06974734" }, { "nct_id": "NCT01097746", "title": "First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fallopian Tube Carcinoma", "Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube Mucinous Adenocarcinoma", "Fallopian Tube Serous Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Fallopian Tube Undifferentiated Carcinoma", "FIGO Stage III Ovarian Cancer", "FIGO Stage IIIA Ovarian Cancer", "FIGO Stage IIIA1 Ovarian Cancer", "FIGO Stage IIIA1(i) Ovarian Cancer", "FIGO Stage IIIA1(ii) Ovarian Cancer", "FIGO Stage IIIA2 Ovarian Cancer", "FIGO Stage IIIB Ovarian Cancer", "FIGO Stage IIIC Ovarian Cancer", "FIGO Stage IVA Ovarian Cancer", "FIGO Stage IVB Ovarian Cancer", "Malignant Ovarian Brenner Tumor", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Mucinous Adenocarcinoma", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Adenocarcinoma", "Ovarian Transitional Cell Carcinoma", "Ovarian Undifferentiated Carcinoma", "Primary Peritoneal Carcinoma", "Primary Peritoneal Serous Adenocarcinoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 33, "start_date": "2010-04-14", "completion_date": "2022-09-13", "has_results": true, "last_update_posted_date": "2022-10-28", "last_synced_at": "2026-09-16T18:13:00.337Z", "location_count": 5, "location_summary": "Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Nassau Bay", "state": "Texas" }, { "city": "Sugar Land", "state": "Texas" }, { "city": "The Woodlands", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01097746" } ] }